Skip to main content
Jilin Aodong Pharmaceutical Group Co., Ltd. logo

Jilin Aodong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000623 ISIN · CNE000000719 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,101 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000623

About Jilin Aodong Pharmaceutical Group Co., Ltd.

https://www.jlaod.com

Jilin Aodong Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacturing, and distribution of therapeutic products, focusing on Traditional Chinese Medicine (TCM), chemical drugs, and health supplements. The product portfolio encompasses cardiovascular medications, gastrointestinal treatments, and various specialized injections and capsules. Notable offerings include the "Anxin" series and other proprietary formulations designed for chronic disease management. The organization prioritizes the modernization of traditional formulas through advanced extraction, purification, and quality control technologies. It maintains extensive production facilities and a dedicated research infrastructure to support product innovation and safety. The company provides medical solutions across multiple therapeutic areas, aiming to bridge traditional healing methodologies with contemporary clinical standards for a diverse patient population.

Recent filings

Filing Released Lang Actions
关于控股子公司获得药品补充申请批准通知书的自愿性信息披露公告
Regulatory Filings Classification · 87% confidence The document is a voluntary corporate announcement regarding a regulatory approval notification for a subsidiary’s drug from the National Medical Products Administration. It does not present financial statements, management changes, dividends, or other specific categories, and is therefore a general regulatory filing. Consequently, it falls under the fallback category Regulatory Filings (RNS).
2026-05-20 Chinese
北京市京都（大连）律师事务所关于吉林敖东药业集团股份有限公司召开2025年度股东会之法律意见书
Regulatory Filings Classification · 55% confidence The document is a legal opinion letter (“法律意见书”) issued by the law firm memorializing the convening procedures, attendance qualifications, and vote procedures/results of the 2025 Annual General Meeting of Jilin Aodong Pharmaceutical Group Co., Ltd. It is not itself the Annual Report, earnings release, proxy statement, nor a shareholder vote announcement by the company to the market. Nor is it a share issue, delisting, or merger communication. There is no specific category for external legal opinions, so it falls under the general “Regulatory Filings” fallback category (RNS).
2026-05-11 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is titled “2025年度股东会决议公告” and provides detailed voting results for each proposal at the shareholders’ meeting, including votes for, against, and abstentions, along with reporting on meeting attendance and legal opinions. It is an official announcement of shareholder vote results rather than the meeting materials themselves or a full financial report. This fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-11 Chinese
关于召开2025年度股东会的提示性公告
Regulatory Filings
2026-05-07 Chinese
关于续聘会计师事务所的公告
Regulatory Filings
2026-04-17 Chinese
2025年度内部控制自我评价报告
Regulatory Filings
2026-04-17 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.